Andrology Xagena

Xagena Mappa
Xagena Newsletter
Medical Meeting

Pfizer: Sildenafil does not increase risk of blindness

Ophthalmologists at the University of Minnesota said that a condition that causes permanent vision loss has been diagnosed in a small group of men who have taken the erectile dysfunction drug Sildenafil ( Viagra ).

Seven patients, aged between 50 and 69 years, had typical features of nonarteritic ischemic optic neuropathy ( NAION ) within 36 hours after ingestion of Viagra for erectile dysfunction. Seven similar cases have been previously reported.

"For years, we've known that some men who take Viagra will experience temporary color changes in their vision and see things as blue or green," said Howard Pomeranz, at the University of Minnesota Medical School. " NAION is a much more serious condition because it can lead to permanent vision loss."

All of the patients had at least one arteriosclerotic risk factor, including hypertension, diabetes, hypercholesterolemia, or hyperlipidemia. All of the patients also had a low cup to disk ratio, which is a way doctors measure the small circular indentation where the optic nerve connects to the eyeball. The low cup to disk ratio means that the blood vessels and nerves are tightly bundled together into the small space in the back of the eye.

"Viagra regulates a chemical in the body to constrict the arteries. This constriction may cut off the blood flow to the optic nerve, especially in people with a low cup to disk ratio, where the blood vessels and nerves are tightly bundled provoking NAION," says Pomeranz.

The onset of NAION within hours after ingestion of Viagra in 14 patients supports an association between the use of the drug and NAION. Based on the fact that 14 cases of NAION have now been reported soon after the use of Viagra, the researchers believe that ophthalmologists should ask all men with NAION about the use of Viagra, and recommend that patients with a history of NAION in one eye be cautioned that Viagra may increase the risk of NAION in the fellow eye.

According to Pfizer, the Viagra's manufacturer, a review of all post-marketing ocular event reports has concluded that there is no evidence of increased risk of blindness among patients taking Viagra.

Pfizer said discussions are progressing with the FDA ( U.S. Food and Drug Administration ) to update the Viagra label to reflect rare reports of non-arteritic anterior ischemic optic neuropathy ( NAION ) in some men who have used the medicine.

While the FDA concluded that no causal relationship between Viagra and NAION has been established, Pfizer has agreed with the agency to include the fact of these reports in the Viagra label to help inform physicians and patients. It is Pfizer's understanding that the FDA has asked that similar information be included in the labels of all oral ED medicines.


1) University of Minnesota, 2005

2) Pfizer, 2005